

Correction to Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B *Streptococcus* Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide

Alberto Nilo, Irene Passalacqua, Monica Fabbrini, Martin Allan, Aimee Usera, Filippo Carboni, Barbara Brogioni, Alfredo Pezzicoli, Jennifer Cobb, Maria Rosaria Romano, Immaculada Margarit, Qi-Ying Hu, Francesco Berti, and Roberto Adamo*

Bioconjugate Chem. **2015**, *26* (8), 1839–1849. DOI: [10.1021/acs.bioconjchem.5b00365](https://doi.org/10.1021/acs.bioconjchem.5b00365)

The original article contained an error in Figure 1 and an omission for Scheme 1. Dr. Sebastien Vidal (University of Lyon, CNRS) is kindly acknowledged for having identified the mistakes in the original paper.




Figure 1. Chemical structure of PSV.

Scheme 1. Synthesis of the modified PSV. For chemical modification is sialic acid, see also Avci, F. Y., Li, X., and Kasper, D. L. (2012) Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines. *Nat. Protoc.* *7*, 2180–2192; and Kim, J. S., Laskowich, E. R., Michon, F., Kaiser, R. E., and Arumugham, R. G. (2006) Monitoring activation sites on polysaccharides by GC–MS. *Anal. Biochem.* *358*, 136–142.